Centessa Pharmaceuticals Reports Director/Officer Changes
Ticker: CNTA · Form: 8-K · Filed: Dec 11, 2025 · CIK: 1847903
| Field | Detail |
|---|---|
| Company | Centessa Pharmaceuticals PLC (CNTA) |
| Form Type | 8-K |
| Filed Date | Dec 11, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $600,000, $6 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, personnel-changes, officer-appointment
TL;DR
Centessa Pharmaceuticals filed an 8-K detailing director and officer changes as of Dec 5, 2025.
AI Summary
Centessa Pharmaceuticals plc filed an 8-K on December 11, 2025, reporting events as of December 5, 2025. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes Regulation FD disclosures and financial statements/exhibits.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy, governance, or operational focus.
Risk Assessment
Risk Level: low — This filing primarily concerns corporate governance and personnel changes, which typically carry a lower immediate risk compared to financial distress or major operational disruptions.
Key Players & Entities
- Centessa Pharmaceuticals plc (company) — Registrant
- December 5, 2025 (date) — Earliest event reported date
- December 11, 2025 (date) — Filing date
FAQ
What specific director or officer positions were affected by the changes reported on December 5, 2025?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' but does not specify the exact individuals or roles in the provided text.
Were there any new directors elected to the Centessa Pharmaceuticals plc board?
The filing lists 'Election of Directors' as an item information, suggesting that new directors may have been elected, but the specific names are not detailed in this excerpt.
What type of compensatory arrangements were made for certain officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item information, indicating that details regarding compensation for specific officers are included, but the specifics are not provided in this text.
Does this 8-K filing include any financial statements?
Yes, the filing explicitly lists 'Financial Statements and Exhibits' as an item information, indicating that financial information is part of the report.
What is the significance of the 'Regulation FD Disclosure' mentioned in the filing?
A Regulation FD Disclosure ensures that material non-public information is disclosed to the public simultaneously, preventing selective disclosure to certain investors.
Filing Stats: 1,122 words · 4 min read · ~4 pages · Grade level 12.1 · Accepted 2025-12-11 07:51:53
Key Financial Figures
- $600,000 — d agreed to increase his base salary to $600,000, effective January 1, 2026, and his tar
- $6 m — with a target grant date fair value of $6 million, with two-thirds of such awards i
Filing Documents
- d933269d8k.htm (8-K) — 31KB
- d933269dex991.htm (EX-99.1) — 14KB
- 0001193125-25-315074.txt ( ) — 213KB
- cnta-20251205.xsd (EX-101.SCH) — 3KB
- cnta-20251205_def.xml (EX-101.DEF) — 15KB
- cnta-20251205_lab.xml (EX-101.LAB) — 24KB
- cnta-20251205_pre.xml (EX-101.PRE) — 16KB
- d933269d8k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 11, 2025 CENTESSA PHARMACEUTICALS PLC By: /s/ John Crowley Name: John Crowley Title: Chief Financial Officer